🇺🇸 FDA

Intelligence · Patent portfolio

Alnylam Netherlands Patents

Full USPTO pharma patent portfolio for Alnylam Netherlands — grant dates, expiration, and drug cross-links.

Patents
379
Expiring ≤24m
4

Quick answer

Alnylam Netherlands has 379 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 4 expire within 24 months — use filters for patent-cliff planning.

Page 1 of 8

  1. US 12416006

    Cell death-inducing DFFA-like effector B (CIDEB) iRNA compositions and methods of use thereof

    Expires Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12404508

    Ketohexokinase (KHK) iRNA compositions and methods of use thereof

    Expires Mon Aug 28 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12397013

    Extrahepatic delivery

    Expires Mon Aug 21 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12385044

    Modified double-stranded RNA agents

    Expires Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12385043

    Modified double-stranded RNA agents

    Expires Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12378553

    Modified double-stranded RNA agents

    Expires Mon Jul 31 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12364762

    Biodegradable lipids for the delivery of active agents

    Expires Mon Jul 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12350338

    Biodegradable lipids for the delivery of active agents

    Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 12343398

    Biodegradable lipids for the delivery of active agents

    Expires Mon Jun 26 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 12338439

    Factor XII (hageman factor) (F12), kallikrein B, plasma (fletcher factor) 1 (KLKB1), and kininogen 1 (KNG1) iRNA compositions and methods of use thereof

    Expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 12331297

    Coagulation factor V (F5) iRNA compositions and methods of use thereof

    Expires Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 12290573

    Modified RNAi agents

    Expires Mon May 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 12241064

    REVERSIR™ compounds

    Expires Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 12239709

    Biodegradable lipids for the delivery of active agents

    Expires Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 12227744

    Compositions and methods for inhibiting expression of transthyretin

    Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 12221607

    Multi-targeted single entity conjugates

    Expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 12173288

    Oligonucleotide-ligand conjugates and process for their preparation

    Expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 12173289

    Hepatitis B virus (HBV) dsRNA agent compositions and methods of use thereof

    Expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 12168767

    Modified double-stranded RNA agents

    Expires Mon Dec 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 12091666

    Xanthine dehydrogenase (XDH) iRNA compositions and methods of use thereof

    Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 12071619

    SERPINA1 iRNA compositions and methods of use thereof

    Expires Mon Aug 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 12059468

    Carbohydrate conjugates as delivery agents for oligonucleotides

    Expires Mon Aug 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 12049628

    Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases

    Expires Mon Jul 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 12049630

    Factor XII (F12) iRNA compositions and methods of use thereof

    Expires Mon Jul 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 12031133

    GNAQ targeted dsRNA compositions and methods for inhibiting expression

    Expires Mon Jul 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 12018260

    Tunable Reversir™ compounds

    Expires Mon Jun 20 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 12005074

    Extrahepatic delivery

    Expires Mon Jun 06 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 11987792

    Compositions and methods for inhibiting expression of the LECT2 gene

    Expires Mon May 16 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 11965166

    Complement factor B (CFB) iRNA compositions and methods of use thereof

    Expires Mon Apr 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 11959081

    Transthyretin (TTR) iRNA compositions and methods of use thereof

    Expires Mon Apr 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 11944687

    Carbohydrate conjugate RNA agents and process for their preparation

    Expires Mon Mar 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 11926832

    Ketohexokinase (KHK) iRNA compositions and methods of use thereof

    Expires Mon Mar 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 11884919

    Lipid formulated compositions and methods for inhibiting expression of serum amyloid a gene

    Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 11873491

    Complement component C5 iRNA compositions and methods of use thereof

    Expires Mon Jan 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 11866710

    Transmembrane protease, serine 6 (TMPRSS6) iRNA compositions and methods of use thereof

    Expires Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 11866701

    Complement component C3 iRNA compositions and methods of use thereof

    Expires Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 11866709

    Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof

    Expires Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 11859185

    Glucokinase (GCK) iRNA compositions and methods of use thereof

    Expires Mon Dec 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 11840692

    Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof

    Expires Mon Dec 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 11834662

    Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof

    Expires Mon Nov 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 11827883

    Dosages and methods for delivering lipid formulated nucleic acid molecules

    Expires Mon Nov 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 11806360

    Compositions and methods for treating transthyretin (TTR) mediated amyloidosis

    Expires Mon Nov 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 11725209

    TMPRSS6 iRNA compositions and methods of use thereof

    Expires Mon Aug 10 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 11725207

    Serpina1 iRNA compositions and methods of use thereof

    Expires Mon Aug 10 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 11685918

    Programmed cell death 1 ligand 1 (PD-L1) iRNA compositions and methods of use thereof

    Expires Mon Jun 22 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 11679158

    Biodegradable lipids for the delivery of active agents

    Expires Mon Jun 15 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 11666653

    Carbohydrate conjugates as delivery agents for oligonucleotides

    Expires Mon Jun 01 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 11649459

    Superoxide dismutase 1 (SOD1) iRNA compositions and methods of use thereof for treating or preventing superoxide dismutase 1-(SOD1-) associated neurodegenerative diseases

    Expires Mon May 11 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Alnylam Netherlands have?

379 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Alnylam Netherlands patents expire?

4 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources · Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.